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 THE EFFECTS OF DIFFERENT CARDIOVASCULAR DEVICES ON CAROTID 
AND AORTIC BARORECEPTORS  
 
KELLY HARMON 
 
ABSTRACT 
 The baroreflex is a well-studied physiological mechanism that provides 
instantaneous nerve impulses to higher brain centers about fluctuations in blood pressure.  
Located within the aortic arch and carotid sinuses, the baroreceptors are 
mechanosensitive stretch receptors activated by physical distention.  When stretched by 
elevated blood pressure, the baroreflex is activated and serves to reduce sympathetic 
nerve activity through increased parasympathetic nerve output, ultimately reducing heart 
rate, contractility and total vascular peripheral resistance.  Therefore, through physical 
perturbation, the baroreflex can be activated and ensuing physiological changes result.  
Several medical devices have been developed to treat and manage cardiovascular 
diseases that are affected by blood pressure dysregulation.  A significant portion of 
devices have their mechanistic application at locations at or near the aortic and carotid 
baroreceptors, which results in alterations of baroreflex activation. This literature review 
serves to highlight three clinically important cardiovascular devices and the effects they 
have on the baroreflex through a summarized review of published work in the scientific 
community.  Intra-aortic balloon pumps, left ventricular assist devices and carotid sinus 
stimulators are cardiovascular devices that have shown promising development and 
iv
 clinical impact since each devices’ initial application in research trials.  Each device has 
been thoroughly reviewed here and the impact that each device has on blood pressure 
regulation has been investigated via available published work.  Results from a limited 
number of studies have shown that each device has a definite effect on baroreflex 
activation and subsequent changes in autonomic nervous system function.  Modifications 
in blood pressure through device use appear to be a potential therapeutic approach to 
managing pathophysiological states, including hypertension and heart failure.  
Hypertension and heart failure will be discussed in greater detail, reviewing current 
approaches to disease management and care.  The results from the available publications 
surrounding device use are specific to certain diseases, however, they are also quite 
generalizable in the sense that these results have shown an overall true effect on blood 
pressure modification by the baroreflex.  Conclusions established from this literature 
review are that although promising work has been recognized through studying these 
cardiovascular devices and their effects on blood pressure regulation, much research and 
development is still needed in order to gain a better understanding of device use and 
impact in the clinical setting. 
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INTRODUCTION 
 Cardiovascular hemodynamics are regulated on a moment-to-moment basis with 
reflex adjustments in mean arterial pressure (MAP) by arterial baroreceptors located in 
the carotid sinus, which is at the level of the internal and external carotid bifurcation, and 
aortic arch. (1) Other baroreceptor locations also include the brachiocephalic and 
common carotid arteries, which have a less substantial impact on blood pressure 
regulation. (2)  The baroreceptors act as a negative feedback control loop, or 
“baroreflex,” as mechanosensitive receptors that relay information to the central nervous 
system about acute changes in MAP.  The Hering nerve, a branch of cranial nerve –IX, 
the glossopharyngeal nerve, carries sensory information from the carotid arteries and 
small vagal branches carry sensory information from the aorta to the nucleus solitarius 
within the medulla oblongata for continual modifications of cardiac output and total 
peripheral resistance. (3)  Control of arterial blood pressure is essential for normal 
vascular homeostasis and, without precise regulation, may lead to various 
pathophysiological issues.  For example, increased MAP increases the demand for 
oxygen by the heart and can lead to “ventricular remodeling, vascular injury, end organ 
damage, and stroke.”  Conversely, a decreased MAP results in less blood delivery to 
tissues and organs and thus, fainting and system shock may ensue. (4)  Due to the 
location of the carotid baroreceptors above the heart and the effects of hydrostatic 
pressure while standing, as well as increased sensitivity to pulse pressure, the carotid 
baroreceptors are vital for modulation of brain pulse pressure and MAP. (5) 
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 The autonomic nervous system (ANS) sympathetic output affects MAP via 
increases in venomotor tone, increased arteriolar constriction and increased heart 
contractility and rate.  Parasympathetic vagal stimulation acts in an opposite fashion to 
sympathetic discharge by decreasing heart contractility, heart rate and venomotor tone, as 
well as causing arteriolar dilation.  The baroreceptors are activated when stretched by 
distension due to increased blood pressure which relays information to the central 
nervous system, resulting in increased cardiac vagal stimulation and a coinciding 
inhibition of sympathetic output to the heart and vasculature.  Therefore, the baroreflex 
acts in response to increased blood pressure by causing excitation of parasympathetic 
stimulation, and during hypotensive states, discharges firing to vagal centers in the brain 
while sympathetic discharge from the central nervous system increases.  Changes in pulse 
pressure sensed by the carotid and aortic baroreceptors adjust vagal output to the heart in 
order to change heart rate swiftly before another beat has completed, whereas 
sympathetic stimulation of contractility, arteriolar tone and heart rate take 2-3 seconds to 
begin its effects (5).  Figure 1 below depicts the afferent and efferent signaling by the 
baroreceptors. 
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Figure 1. Baroreflex signaling. Depiction of the afferent and efferent nerve signaling 
involved in the baroreflex mechanism.  Input from the aortic and carotid baroreceptors 
merge within the vasomotor center (VMC), where efferent signals are then produced to 
generate an autonomic response. Figure taken from (5). 
Due to the significance of the arterial baroreceptors within the cardiovascular 
system and their important physiological role in regulating hemodynamic states, it is of 
great interest to consider cardiac devices and how they affect the baroreflex.  This paper 
will provide relevant background information on the importance of blood pressure 
regulation, baroreceptor function, major discoveries and therapies effecting blood 
pressure regulation, including drug, diet and device treatments. Thereafter, an in-depth 
discussion of three cardiac devices will be explored and compared, as well as future 
directions of cardiovascular device therapies. 
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Vessel anatomy and arterial function 
 Cardiovascular circulation, beginning at the heart, pumps blood through the more-
resistant arterial tree, into small, single cell-lined capillaries, and then further into the 
compliant venous circulation, ultimately returning to the heart to complete the circuit.  
The structural layers of these types of vessels are altered depending on location and 
function.  The differences in vessel type and vessel wall layers are important throughout 
the circulatory path of blood flow, and will be discussed in further detail below. (6) (7) 
(8)  
Blood vessels are made up of three layers which include: the tunica intima, the 
innermost layer, the tunica media, the middle layer, and the tunica adventitia, or externa, 
the outermost layer (Figure 2).  The tunica intima surrounds the vessel lumen as a layer 
of endothelial cells that are adjacent to the basement membrane, separating the tunica 
intima from the tunica media.  Depending on the type of vessel, varying layers of smooth 
muscle cells compose the tunica media, which act to contract the vessel and adjust 
vascular tone.  Surrounding the tunica media, the tunica adventitia is a combination of 
connective tissue components that include “loose extracellular matrix, fibroblasts, nerves 
and small arteries.” (9)  For the purposes of this paper, only the arterial side of the 
circulatory system will be discussed in further detail.  
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Figure 2. Arterial structure. The layers of arteries. The tunica externa 
(adventitia) is the outermost layer, the tunica media is the middle layer, and the tunica 
intima is the innermost layer. Figure taken from (10).  
 
 Arteries can be classified as elastic or muscular, large or small, or arterioles, the 
smallest vessels of the arterial circulation.  The location of these vessels depends on their 
proximity to the heart.  Beginning at the aorta, the largest arteries, also known as 
“Windkessel vessels,” have elastic properties for distributing a blood supply to the head, 
neck and limbs.  As blood flow moves further through the arterial tree, vessels gradually 
decrease in size and shift from blood distributing properties to more resistant features, as 
well as transition from elastic to muscular vessels, ultimately ending as arterioles that 
merge with capillary beds. (2) (11)  
Primarily, different types of arteries can be distinguished by the components of 
the tunica media.  The tunica media of elastic arteries contains a significant amount of 
elastic tissue in comparison to smooth muscle fibers, which are arranged as sets of 
 6 
concentric rings within the layer.  During blood flow, the elastic properties of elastic 
arteries allows for continual distention and recoiling of the artery wall as blood is pumped 
through the vessels.  As for the tunica media of muscular arteries, this layer houses a 
considerable amount of smooth muscle cells that are organized in a circular fashion.  
Smooth muscle cells allow for more precise control of muscular arteries via 
vasoconstriction and vasodilation. (12)  The changing characteristics of the tunica media 
between the various vessels plays a significant role in the progression of blood flow 
throughout the arterial tree.  As the heart pumps blood at a high pressure, pulsating waves 
are generated through the elastic expansion and recoil of larger arteries until reaching 
medium and small-sized arteries that continue the progression of blood flow via smooth 
muscle constriction and dilation.  The elastic properties of larger vessels serve to dampen 
the pulse of blood flow, while distributing an adequate volume of blood.  As the vessel’s 
tunica media gradually gains more smooth muscle fibers, this functions to continue blood 
distribution, while more significantly providing increased resistance, resulting in more 
precisely controlled blood pressure and flow regulation. (11) 
As the tunica media changes throughout the arterial vasculature, so do the layers 
of tunica intima and tunica adventitia, although less significantly.  While not as distinct as 
the variations in the tunica media, changes can be observed as the vessel wall thins and 
the lumen decreases in size.  Throughout all of the arterial tree into the arterioles, the 
tunica intima is still existent, as well as the connective tissue components that make up 
the tunica adventitia.  This is in contrast to the tunica media, which has gradually 
changing properties until reaching the arterioles, where elastic fibers are nonexistent and 
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only a single layer of smooth muscle cells are found.  As arterioles decrease in size, the 
three layers of tunics become less distinct, with the smallest arterioles having little lining 
and one layer of smooth muscle cells. (13) 
Following the path from the heart, as vessels decrease in size, so do the numbers 
of elastic fibers, while the amount of smooth muscle cells increases. (14)  Continuing into 
smaller vasculature, arteries gradually become arterioles, as the terminal ends of the 
arterial tree prior to capillary vessels.  The bulk of vascular resistance is generated from 
arterioles, having a significant role in hemodynamic regulation and tissue perfusion.  As 
mentioned previously, arterioles contain only one to two layers of smooth muscle cells, 
and are considered to be primary “resistance vasculature that provides in excess of 80% 
of the resistance to blood flow in the body.” (15)  
In order to keep the body hemodynamically stable, the arteries function to supply 
the peripheral tissues and organs with a sufficient amount of blood, and to perfuse the 
tissues and organs at a steady rate via intricate capillary beds.  The effectiveness of the 
blood supply is delegated by artery size.  Larger, elastic arteries have much less 
resistance to blood flow and also act to support an adequate blood supply.  Tissue 
perfusion rate is controlled by arteries in order to lessen high pressure oscillations and 
establish a balanced blood flow. (16)  As arteries provide high resistance, they do so in 
order to distribute blood flow appropriately to the capillary bed microcirculation, which 
contains only endothelial cells and a basement membrane.  It is within the capillary beds 
that the primary exchange of nutrients and waste products occur.  Oxygen, carbon 
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dioxide, proteins, electrolytes, water, circulating hormones and metabolic by-products 
and substrates are exchanged between the capillary lumen and surrounding tissues. (11) 
 
Baroreceptors and the importance of blood pressure regulation  
 Initial discovery of the baroreceptors in the 1920’s began when massaging of the 
neck produced reflex alterations in blood pressure and heart rate. (17)  The baroreceptors 
are considered stretch receptors which contain sensory nerve endings that function to 
sense changes in pressure within the arterial wall.  They are located within large arteries 
and the walls of the heart, and for the purposes of this paper, only the baroreceptors 
within vessels will be reviewed in great detail. (18)  The cell bodies are located with the 
elastic layers of the vessels themselves, with baroreceptor nerve endings terminating 
within the tunica adventitia. (19) (20)  Some literature has also described the 
baroreceptors to terminate at the medial-adventitial margin in both the aortic and carotid 
positions. (21)  The location of the baroreceptors among different vessels originates from 
the branches of the aorta (Figure 3).  The baroreceptors can be found in the following 
locations of the arterial tree: the aortic arch, brachiocephalic artery and carotid sinuses, as 
well as in the common carotid arteries, however, these areas do not play a significant role 
in blood pressure regulation in humans.  The aortic arch baroreceptors can be further 
defined by location as initiating at the beginning of the left subclavian artery and 
Botallo’s duct, while the brachiocephalic artery contains baroreceptors at its origin and its 
bifurcation into the right common carotid and subclavian arteries. (2)   
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It is important to note that there are two classifications of baroreceptors: high-
pressure and low-pressure.  The arterial baroreceptors are considered high-pressure 
baroreceptors, whereas the cardiopulmonary receptors are considered low-pressure.  As 
the focus of this literature review is on the high-pressure arterial baroreceptors, only a 
brief summary of the low-pressure cardiopulmonary baroreceptors will be discussed here.  
These receptors are found within the chambers of the heart, large systemic veins and in 
pulmonary circulation. (18)  Imbedded within the walls of the heart, both the atrial and 
ventricular cardiopulmonary receptors provide reflex changes, but it is the ventricular 
receptors that prove to be most vital as pressures inside of the heart chambers decrease.  
The main characteristic of cardiopulmonary receptors is that they serve as sensors of 
changes in fluid volume.  The receptor nerve fibers synapse within the vagus nerve, 
therefore as fluid volume increases and the receptors are stretched, parasympathetic 
activity is generated, ultimately causing alterations in cardiovascular and renal function. 
(22)  As the cardiopulmonary receptors fire at a “low basal discharge rate,” they act as a 
negative feedback mechanism that is inhibitory to TPR via increased parasympathetic 
discharge. (23)  Conversely, as fluid volume decreases and the stretch of the receptors is 
lessened, parasympathetic activity decreases to the heart and vessels. (24) 
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Figure 3. Baroreceptor location. Location of baroreceptors within the carotid 
sinus and aortic arch.  The carotid baroreceptors are innervated by the carotid sinus nerve, 
which is a branch of the glossopharyngeal nerve, and the aortic baroreceptors are 
innervated by the aortic depressor nerve, which is a branch of the vagus nerve. Figure 
taken from (25).   
 
 As seen in Figure 3, the aortic arch baroreceptors are innervated by an afferent 
branch of the vagus nerve, known as the aortic depressor nerve.  Additionally, the carotid 
baroreceptors are innervated by an afferent branch of the glossopharyngeal nerve, the 
carotid sinus nerve. (25)  Baroreceptors located within the carotid sinus, which is 
contained within the internal carotid arteries, have been shown to be the major 
contributor to MAP regulation, compared to the receptors found in the aortic arch, 
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therefore, their innervation and signaling to higher centers in the brain will be discussed 
here in greater detail. (26)  As the carotid baroreceptors sense an increase in pressure 
within the vessel, an electrical signal is sent via sinus nerve afferent fibers, and further by 
the glossopharyngeal nerve, to medullary centers in the brain. (27)  The axon signal 
reaches its synaptic location in the brain at the nucleus tractus solitarius (NTS), which 
resides in the medulla oblongata.  The NTS is an assembly of nuclei that receives sensory 
input and projects to regions that provide motor output via autonomic regulation to 
maintain body homeostasis.  Its structure resembles the letter “V,” and depending on the 
location of neurons, it relays varying signals from different organ systems.  These 
different NTS areas “serve gustatory, cardiovascular/respiratory, and gastrointestinal 
functions.” (28)  Continuing from then NTS, neuronal projections synapse with the 
caudal ventrolateral medulla (CVLM), which is a part of the ventrolateral medulla.  The 
CVLM is located caudal to the rostral ventrolateral medulla (RVLM), and contains 
inhibitory interneurons which regulate RVLM signal output.  The RVLM serves to 
generate sympathetic output to peripheral locations within the body.  Therefore, as MAP 
begins to increase, baroreceptor signaling occurs, and the end result is an inhibition of 
sympathetic activity to different organ targets and precise cardiovascular control. (27)  
Figure 4 below depicts these synaptic pathways. 
 12 
   
Figure 4. Carotid baroreceptor signaling. Diagram displaying carotid 
baroreceptor signaling to the medullary cardiovascular center within the brain and key 
efferent signaling targets in the periphery.  As the baroreceptors are stimulated (as shown 
here via electrical stimulation), sensory information is sent via the glossopharyngeal 
nerve to the NTS within the medullary cardiovascular center.  From the NTS, the 
information is relayed to the CVLM, which acts in an inhibitory fashion (shown as 
dashed lines above) to the RVLM, inhibiting sympathetic outflow of efferent signaling to 
peripheral organs.  Figure taken from (27). 
 
Acute blood pressure regulation is clearly a very sensitive dynamic that is 
modulated very closely in a negative feedback manner by the baroreceptors.  In the short 
term, as MAP varies, the response of the baroreceptors happens quickly to alter 
downstream sympathetic and parasympathetic output.  As MAP increases, baroreceptors 
firing leads to increased parasympathetic activity and decreased sympathetic activity, 
with subsequent effects on the cardiovascular system, including reduced heart 
contractility, heart rate, venous return and total peripheral resistance (TPR).  As MAP 
decreases, baroreceptors have a decreased pressure sensed, which dampens firing and 
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enhances sympathetic discharge and decreases parasympathetic discharge, resulting in 
increased heart contractility, heart rate, venous return and TPR.  It is important to note 
that the sympathetic and parasympathetic responses facilitated by baroreceptor activity do 
not happen in identical time frames.  As parasympathetic activity is activated, it does so 
in an almost instantaneous fashion, on the order of milliseconds.  In contrast, sympathetic 
discharge is delayed, taking two to three seconds to activate and longer for maximal 
results to be reached. (26) 
Several other physiological mechanisms contribute to the baroreceptor function 
and maintaining normal blood pressure levels.  One such example impacting the 
baroreflex occurs during breathing; a physiological process termed “respiratory gate” 
affects heart rate by opposing methods during respiration.  Inspiration reduces 
baroreceptor vagal motor neuron stimulation, whereas expiration increases it.  This 
example and others, such as environmental, humoral and behavioral elements, influence 
the baroreceptor regulation of MAP. (26)  Other systems also have a significant bearing 
on blood pressure modulation.  These systems include: the renin-angiotensin-aldosterone 
system to maintain vascular tone and volume homeostasis, the adrenergic receptor system 
to alter heart contraction, vascular tone and heart rate, heart and brain natriuretic peptides 
and the kinin-kallikrein system to maintain renal salt management and vascular tone.  
Additionally, the blood vessels generate numerous elements that act locally to cause 
vasoconstriction and vasodilation as they are released into the bloodstream. (29)  Long-
term blood pressure regulation within the body is predominately assumed by the kidneys.  
The renal system acts to keep a steady balance of fluid volume over time to ensure that 
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the intake and output of water and electrolytes, mainly sodium, are stable.  As water and 
sodium balance are regulated, MAP is continually adjusted over time to provide the 
kidneys with adequate perfusion to perform their fluid balance duties. (30) 
Blood pressure regulation is vital to maintain body homeostasis, as with any 
changes from normal, pathophysiological states can develop.  MAP is closely related to 
cardiac output and TPR, therefore an alteration in either direction has a wide effect on 
other cardiovascular mechanisms.  With sustained higher levels of blood pressure, or 
hypertension, “end-organ damage” can result. (31)  Hypertension is a significant risk 
factor for “stroke, myocardial infarction, congestive heart failure, and end-stage renal 
disease,” demonstrating the importance of baroreceptor function in acute blood pressure 
changes that with dysfunction over time, can result in many diseases affecting a vast 
range of patient populations. (29)  As hypertension is a significant risk factor for disease, 
low blood pressure, or hypotension, is also problematic.  Hypotension can lead to 
decreased nutrient and oxygen delivery, depriving tissues and depleting organ’s abilities 
to maintain adequate operating conditions, potentially leading to fainting, an insufficient 
blood supply to organs, or system shock. (31) (32) 
Baroreflex failure also demonstrates the major role the baroreceptors play in the 
cardiovascular system.  This phenomenon typically occurs as result of a physical trauma 
or radiation to the carotid sinus or glossopharyngeal nerves, leading to symptoms of 
continuous high blood pressure, headache and increased heart rate.  Encephalopathy and 
cerebral hemorrhage can transpire as systolic blood pressure rises over 250 mmHg in 
acute baroreflex failure.  Chronically, baroreflex failure can produce “volatile 
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hypertension,” which appears usually days to weeks after initial failure. (17)  Volatile 
hypertension is categorized by sudden changes in sympathetic activation that lead to 
increases in blood pressure.  The baseline blood pressure may be within the normal range 
or elevated, but sudden surges in blood pressure, with associated increased heart rate, 
may occur for minutes to hours during a single episode. (33)  Moreover, volatile 
hypertension continues to be aggravated by the body’s response to increase sympathetic 
activity even further. (34)  Due to a heightened sensitivity of sympathetic discharge, 
physical and mental triggers can yield rushes of volatile hypertension and increased heart 
rate.  These triggers may include “exercise, cold and sexual arousal,” or stressful mental 
states.  Other symptoms of amplified sympathetic action are listed in Table 1.  
Additionally, opposing effects of hypotension may be produced in between highly active 
hypertensive states.  Hypotension, asystole and decreased heart rate can sometimes be 
seen, particularly during the hours of sleep.  Further symptoms of hypotension due to 
baroreflex failure are summarized in Table 1. (17)  It should also be noted that baroreflex 
failure does not necessarily have to occur at the level of receptors themselves; damage to 
the synaptic pathway signaling to or from the NTS can also demonstrate symptoms of 
baroreflex failure. (35)  Table 1 below lists the side effects associated with baroreflex 
failure. 
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Table 1. Symptoms and signs of baroreflex failure. Table taken from (17).  
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THERAPEUTIC METHODS & BLOOD PRESSURE; A MULTITUDE OF 
OPTIONS  
 Blood pressure abnormalities can lead to a plethora of pathophysiological states, 
with hypertension being the leading risk factor for disease.  Sabbahi et. al. have described 
that approximately “one in every three Americans has one or more types of 
cardiovascular disease, and nearly the same percentage have hypertension.”  They go on 
to state that 17.3% of these individuals are unaware of their underlying condition, and 
that roughly 50% of patients receiving any form of therapeutic treatment are able to keep 
their blood pressure under control.  Additionally, their statements regarding the 
healthcare costs surrounding hypertension was that it totaled roughly $46.4 billion in 
2011, with anticipated costs to rise close to “six-fold by 2030.” (36)   
It is of no surprise then, that significant efforts in research and development have 
resulted in therapies to treat and manage disorders in blood pressure dysregulation.   
Given that hypertension has been described as the leading risk factor for disease, several 
possible treatment options will be considered in this review.  First, this review will 
explore prescribed diet and exercise regimens directed at improving blood pressure 
regulation. Thereafter, drug therapies focused on hypertension will be discussed, and 
lastly, device therapies will be described.  
 
Diet and exercise 
  Hypertension can be defined as blood pressure within the arteries that reaches or 
exceeds 140mmHg for systolic blood pressure and 90mmHg for diastolic blood pressure.  
Throughout a majority of patient populations, a positive correlation can be seen amongst 
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“systolic blood pressure and risk of cardiovascular mortality, cardiovascular events and 
strokes.” (37) Globally, given its impact on morbidity and mortality, hypertension is 
high on the list of preventable diseases that result in early death.  A multitude of research 
has verified that decreasing one’s blood pressure decreases the risk of cardiovascular 
disease.  Padmanabhan et. al. (2010) indicated that “for every 2 mm Hg decrease in mean 
systolic blood pressure, there is a 7% reduction in the risk of ischemic heart disease 
mortality, and a 10% reduction in the risk of stroke mortality.”  The authors also go on to 
state that individuals of any age who decrease their blood pressure by 20mmHg, decrease 
their risk of cardiovascular disease by 50% (38).  Figure 5 below depicts reductions in 
blood pressure from a studied population, and the resultant reductions in mortality 
percentages for associated diseases. 
 
Figure 5. Population-based distributions of systolic blood pressure after 
intervention.  Systolic blood pressure distributions pre- and post- therapeutic 
intervention in a population-based intervention strategy, as well as the decrease in 
mortality.  Public health approaches of intervention include: decreasing sodium or caloric 
density in supplied foods, providing desirable exercise opportunities and increasing 
access to appropriate community facilities.  SBP, systolic blood pressure; BP, blood 
pressure; CHD, coronary heart disease. Figure taken from (39).  
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Several distinguishable patient risk factors have been identified for diagnosing 
individuals at risk for hypertension.  These identifiers consist of, but are not limited to: 
advancing age, high BMI, ethnicity, sex, hereditary factors, baseline blood pressure and 
measurements of aldosterone secretion in the urine and plasma renin activity. (38)  Other 
lifestyle factors include increased alcohol ingestion, high sodium and low potassium 
intake through diet and an inactive standard of living. (39)   
Blood pressure regulation is clearly affected by several factors, some of which are 
out of an individual’s control, and others which can be modified by lifestyle changes.  
Diet and exercise play a key role in blood pressure regulation and can be driven 
prophylactically to prevent cardiovascular disease, or introduced as lifestyle adjustments 
as first steps to treat and manage hypertension.  For the treatment of hypertension, 
patients are informed to maintain a healthy diet, become more active through regular 
physical exercise and lose weight if they are currently overweight or obese. (40)   
There are many established diets that individuals with hypertension are 
recommended to follow in order to lower blood pressure and reduce the risk of significant 
morbidity and mortality (40).  Although slightly different in each approach of various 
food groups and daily recommended intake, each diet is heavily focused on wholesome 
and natural foods instead of processed and artificial ingredients.  Three diets that aim to 
reduce elevated blood pressure and therefore, alter blood pressure regulation, will be 
briefly discussed here.  These diets include the Mediterranean diet, the Dietary 
Approaches to Stop Hypertension (DASH) diet and the less commonly known, Nordic 
diet. (40) 
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The Mediterranean diet was recognized from different countries around the 
Mediterranean basin in the 1950’s for its emphasis on rural and agriculturally-based 
foods. (41)  Foods typically consumed in this diet include fresh produce, olive oil, 
legumes, fish, nuts and whole grains, as well as a reasonable intake of red wine.  The diet 
also recommends a low consumption of red meats, sugar and dairy products.  The latter 
food groups, in combination with artificial and processed foods, are what 
characteristically make up the Western diet that is more commonly adapted in unhealthy 
lifestyles.  Literature reviews of randomized controlled trials have concluded that 
individuals following a Mediterranean diet lowered their blood pressure significantly, 
along with several other cardiac risk factors such as LDL and total cholesterol and body 
weight. (42) 
The DASH diet was created by the National Heart, Lung and Blood Institute to 
advise individuals with hypertension on how to manage and, potentially reduce their 
blood pressure, both in the chronic and acute settings, through diet alterations.  Generally, 
a DASH diet is low in all fats (particularly saturated fats), sodium, sugars and cholesterol.  
Published research has shown that people following a DASH diet have a reduced “risk of 
coronary heart disease that can result from hypertension.”  Research has also shown that 
people living with chronic hypertension have the potential to be medication-free if they 
maintain their blood pressure through healthy diet and lifestyle choices. (43)  In addition 
to the positive effects of chronic modification and maintenance of hypertension, the 
DASH diet has been shown to lower ambulatory blood pressure levels measured at 24 
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hours, as well as throughout time points during the day and evening.  These results were 
viewed across several classifications, such as ethnicities, sex and age groups. (44) 
The Nordic diet, also known as the Baltic Sea diet, incorporates foods that are 
understood to have properties that promote good health.  The Nordic countries of 
Norway, Sweden, Finland and Denmark cultivate and consume low-fat dairy products, 
barley, oats and rye, salmon, fruits including berries and apples, and vegetables including 
leafy greens, root vegetables, tomatoes, cucumbers, peas and cabbages. All of these foods 
are considered to have “health-enhancing features.”  Additionally, low amounts of 
alcohol, red meats and fat are consumed. (45)  Results from studies have shown that this 
less-commonly known diet has produced significant effects in reducing blood pressure in 
the compared trials.  Further investigation of the Nordic diet to manage hypertension is 
warranted. (40) 
Other interesting dietary factors come into play with blood pressure regulation.  
One particular group of metabolites has gained interest in the cardiovascular community 
for its correlation with cardiovascular and chronic disease. Quercetin is a metabolite of 
many common foods consumed in the Nordic diet, and is a polyphenolic flavonoid.  It is 
found in berries, onions, apples, red grapes, citrus fruits, bark roots, broccoli, tea, red 
wine and flowers, and has been shown to have blood pressure lowering effects in 
hypertensive human and animal models.  Due to a limited amount of published literature 
on quercetin its impact on cardiovascular heath, the exact mechanism by which 
quercetin’s effects are carried out are still uncertain.  Some hypotheses include: enhanced 
endothelial function, reduced oxidative stress, direct impact on vascular smooth muscle, 
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angiotensin-converting enzyme (ACE) inhibition and alteration of gene expression and 
cell signaling.  Although an exact mechanism has yet to be determined, it is evident that 
quercetin interacts with several targets that are of future interest in studying its blood 
pressure lowering properties. (46) 
As previously discussed, diet undoubtedly plays an important role in blood 
pressure regulation and the serious impact on long-term health and wellbeing.  It is 
interesting to note, however, that there are acute effects on blood pressure, immediately 
after food consumption.  When food is consumed, signals from different areas of the 
body are relayed to the brain in order to prepare for digestion, metabolism and 
appropriate storage of nutrients.  “Postprandial activation” occurs through nervous and 
hormonal system participation, and in particular, through sympathetic nervous system 
activation.  This activation, which is governed in part by the baroreceptors, is necessary 
to direct blood flow and moderate blood pressure in order to support the digestion of food 
intake.  After a meal, the relocation of blood flow also produces thermogenic responses 
due to the energy expenditure necessary for tissues to absorb nutrients needed 
instantaneously, or to be stored for later use.  The baroreceptors play a role in food 
digestion during the post-prandial state as vessels begin to vasodilate.  As food is 
consumed, vessels within the periphery vasodilate, which is immediately sensed by the 
baroreceptors as a decrease in blood pressure, causing afferent signaling to the central 
nervous system and activation of the sympathetic nervous system.  Consequently, it is 
quite clear that diet, in the acute sense of meal-to-meal activity, has a rapid effect on 
blood pressure regulation and the baroreceptor response. (47) 
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Along with diet, physical exercise is another non-pharmacological factor 
constantly influencing blood pressure regulation.  As exercise is initiated, the 
baroreceptors are key players in modifying the cardiovascular response to support the 
body’s demand for an adequate oxygen supply and tissue perfusion.  Beat-to-beat 
fluctuations in blood pressure are sensed by the stretch receptors in the carotid arteries 
and aortic arch and an autonomic nervous system response is generated, ensuring 
sufficient cardiac output and appropriate changes in TPR are maintained.  Research has 
shown that throughout low, moderate and heavy exercise, the baroreceptors will “reset” 
to adjust to the blood pressure increases produced during exercise.  This resetting is 
thought to be a combination of several mechanisms; the baroreceptors appear to work in 
conjunction with central signaling from higher brain centers, an “exercise pressor reflex,” 
caused by contracting skeletal muscle and signals generated from the cardiopulmonary 
receptors in the heart, lungs and large veins.  The influence of physical exercise on the 
baroreflex has clearly been shown to have significant impact on blood pressure 
regulation. (3) 
Exercise and the arterial baroreflex response is mediated in an “intensity-
dependent” fashion, although as previously described, a range of intensities from low to 
extreme do evoke a baroreceptor signaling reaction.  The neural inputs from the carotid 
and aortic baroreceptors, central command of higher brain centers and the exercise 
pressor reflex are well understood, whereas the literature published focused on the 
cardiopulmonary receptor response is limited.  Once thought to be absent during exercise, 
the baroreceptor response functions to maintain an unchanged reflex sensitivity as heart 
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rate and blood pressure increase, which allows for its resetting and ability to operate at 
demanding MAP levels as well as it does at rest.  The baroreflex, along with the 
aforementioned neural inputs, generates the body’s response to exercise as a complex 
system of sympathetic and parasympathetic mechanisms in order to maintain adequate 
blood pressure levels.  Figure 6 below highlights these inputs and their outcomes to 
modulate MAP via changes in heart stroke volume, heart rate, cardiac output and 
vasculature alterations in peripheral vessels. (21)
 
Figure 6. Afferent and efferent signaling with resultant cardiovascular 
changes during exercise. Contributions of the neural mechanisms involved with 
adjustments to cardiovascular hemodynamics during exercise. Central command signals 
from the brain, arterial baroreceptors, cardiopulmonary receptors and the exercise pressor 
reflex influence the sympathetic and parasympathetic activity modifications during 
exercise. The resultant changes in autonomic output modify heart rate, contractility, 
vessel diameter and total vascular conductance to allow for proper blood pressure levels 
during exercise. MAP, mean arterial pressure; HR, heart rate; SV, stroke volume; TVC, 
total vascular conductance; ACh, acetylcholine; NA, noradrenaline. Figure taken from 
(21). 
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Pharmaceutical agents 
The targets of antihypertensive medications focus on specific areas of blood 
pressure regulation, with each pharmaceutical agent having its own unique mode of 
action. (38)  There are currently several antihypertensive drugs available by prescription.  
Common oral antihypertensive agents include: angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin II receptor (ARB) blockers, calcium channel blockers, alpha 1-
receptor blockers, beta receptor blockers, central alpha-2 receptor agonists, diuretics and 
direct vasodilators.  If necessary to achieve optimal blood pressure levels, some 
medications may be used in combination.  Additionally, the dosage and frequency of 
medication vary between and within groups of drugs. (48)  For the purposes of this 
review, a brief overview of the more common antihypertensive medications will be 
discussed.  
ACE inhibitors play a role in reducing elevated blood pressure by stabilizing the 
renin-angiotensin-aldosterone and kallikrein-kinin systems.  This class of medications 
stops the production of the angiotensin II by inhibiting the enzyme that converts 
angiotensin I to angiotensin II.  As the angiotensin-converting enzyme is inhibited, the 
result is a reduction in TPR.  This decrease in vessel resistance allows for increased renal 
plasma flow within the vasculature of the kidneys and thereafter, an increased excretion 
of sodium.  A “renoprotective” result is also generated through increased dilation of the 
nephron’s efferent arteriole, which reduces pressure within the nephron and the amount 
of protein that is filtered and excreted.  Moreover, ACE inhibitors have anti-inflammatory 
effects and reduce growth factor release that are beneficial to the health of the kidneys. 
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(49)  As ACE inhibitors take effect by modifying the balance between these two systems, 
the overall result is a tightly regulated extracellular fluid volume and a reduction in blood 
pressure. (50) 
Antihypertensive angiotensin receptor blocker (ARB) medications are similar in 
fashion to ACE inhibitors in that the renin-angiotensin-aldosterone system is again 
targeted; their mode of action, however, differs.  ARB’s act by blocking the stimulation 
of the angiotensin II receptor, while ACE inhibitors halt the production of the angiotensin 
II enzyme itself. (51)  Angiotensin II targets two receptors for its physiological effects: 
Ang II type 1 receptor and type 2 receptor.  The pharmacological properties of ARB 
medications have their methods of action targeted to the type 1 receptors to produce the 
antihypertensive effects of this drug class. (52) 
Calcium channel blockers are pharmaceutical agents which inhibit vascular 
voltage-gated calcium channels, diminishing the amount of free intracellular calcium.  
This results in less available calcium, and therefore decreased smooth muscle contraction.  
As the smooth muscle relaxes within the arterial blood vessel, blood vessel diameter 
increases and thus, blood pressure decreases. (53)  Additionally, as arterial diameter 
increases, the arterial resistance in the vessel decreases, adding to calcium channel 
blocker’s antihypertensive properties. (54) 
Alpha and beta blockers are classes of medications which target adrenergic 
receptors located throughout the body.  From a cardiovascular standpoint, the receptor 
types that play a major physiological role are alpha-1, beta-1 and beta-2.  Alpha-1 
receptors have been viewed as pharmaceutical targets for their involvement in 
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vasoconstriction of large resistance blood vessels, the aorta and the coronary arteries, 
contraction of the heart and heart rate.  Beta-1 receptors serve to alter the activity of 
catecholamines centrally within the heart, whereas beta-2 receptors effect the peripheral 
tissue vasculature with vasodilating methods of action.  It has been clearly established 
that blocking the alpha-1 receptor results in lowered blood pressure by reducing its 
vasoconstrictive actions; what is not clear is precisely how beta blockers produce reduced 
arterial blood pressure effects.  Suggested methodologies consist of beta blockers 
effecting the renin-angiotensin-aldosterone system by decreasing renin formation, 
controlling the sympathetic nervous system, or reducing cardiac output.  The 
antihypertensive result is proposed to potentially be a mixture of all three physiological 
responses. (55) 
Diuretics for the treatment of hypertension are typically in the form of thiazide or 
thiazide-like diuretics, or non-thiazide loop diuretics.  Both classes generate their 
pharmacological properties by causing the kidneys to get rid of excess sodium in the 
body.  Certain types of thiazide and thiazide-like diuretics also produce vasodilation in 
the vasculature. (56)  By inhibiting the sodium-chloride cotransporters in the distal 
convoluted tubule of the nephron, sodium and water are unable to be reabsorbed, 
therefore, allowing for excess excretion and an overall decrease in fluid volume.  This 
characteristic of thiazide and thiazide-like diuretics has been well established in the acute 
setting, but similar to beta blockers, the long-term overall hypotensive effects of these 
medications are not fully understood. (57)  Loop diuretics also produce inhibitory actions 
on the nephron, however, their pharmacologic target are the sodium-potassium-chloride 
 28 
cotransporters located in the in the loop of Henle.  The overall result of diuresis causes 
similar hypotensive results as fluid is lost from the body.  Additionally, similar to thiazide 
and thiazide-like diuretics, loop diuretics also have vasodilatory properties that contribute 
to their antihypertensive effects. (58) 
 
Interventional and device therapies 
During the 1950’s, the significance of autonomic regulation of the cardiovascular 
system was discovered as sympathectomy was observed to cause strong antiarrhythmic 
properties in experiments.  Since then, the importance of the baroreflex and its regulation 
of blood pressure has been of great interest in the interventional and device therapeutic 
worlds.  A subset of therapies will be discussed briefly here, before delving deeper into 
three specific cardiovascular devices.  The first set of interventional approaches that have 
an impact on the baroreflex to be considered here are lower body negative pressure, vagal 
nerve stimulation, renal denervation, spinal cord stimulation and carotid angioplasty and 
stenting. (59) 
Lower body negative pressure is a technique designed to decrease central blood 
volume by shunting blood from the thoracic region to the lower half of the body.  This 
technique has been used typically to study hemorrhage, aerospace physiological changes 
and orthostatic blood pressure.  As a therapeutic machine delivers lower body negative 
pressure to an individual, the venous return of blood is reduced, creating a lessened stroke 
volume and preload on the heart. (60)  This relocating of blood volume produces 
orthostatic stress, which is sensed by the baroreceptors as a hypotensive state; studies 
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have referred to this as “baroreceptor unloading.”  As this occurs, the baroreflex activates 
the sympathetic nervous system to attempt to bring the body back to a hemodynamically 
stable state. (61) 
A technique less commonly adapted in the clinical setting is vagal nerve 
stimulation.  Immense research and development have gone into producing therapies for 
sympathetic activation, however, parasympathetic activation by interventional 
approaches remains to be explored.  Parasympathetic innervation of the heart derives 
from the vagus nerve, as well as contributions from parasympathetic thoracic ganglia, 
which allow for mechanisms of “negative inotropic and chronotropic effects.” (62)  
When applied at low levels, vagal stimulation has been shown to improve cardiovascular 
functioning in certain patient populations.  It appears that this “cardioprotective” result is 
implemented in both the atria and ventricles.  Studies of patients with heart failure have 
shown improved cardiovascular functioning in the chronic setting through vagal nerve 
stimulation. (63)   
The range of literature surrounding vagal nerve stimulation and its impact on the 
baroreflex and blood pressure regulation in the acute setting is currently quite narrow.  
One report describes patients going through coronary artery bypass graft (CABG) surgery 
or carotid endarterectomy who had vagal nerve stimulation during these procedures.  The 
resulting blood pressure effects were a “frequency-dependent” decrease in systolic blood 
pressure only, as well as a reduction in heart rate. (62)  The obstacles found when 
attempting to evaluate changes in the baroreflex response and cardiovascular 
hemodynamics during vagal nerve stimulation were estimating heart rate during a 
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continual balance of efferent and afferent signals.  Published work has described heart 
rate to be changed very minimally, which makes evaluating an actual autonomic response 
difficult.  As afferent and efferent signals are produced, they are roused in a stable 
fashion, which improve parasympathetic vagal activation in the heart and a result in a 
nominal change in heart rate. (63) Therefore, it is clear that continued research efforts are 
necessary to understand the effects of parasympathetic activation on the baroreflex via 
vagal nerve stimulation, and resultant acute alterations in blood pressure. 
Hypertension treatment for patients who undergo procedural interventions to 
reduce the sustained high levels of MAP may target the elevated sympathetic stimulation.  
As previously discussed, the baroreceptors and cardiopulmonary receptors are principal 
targets for treatment focused on sympathetic activation.  Renal denervation is another 
therapeutic technique that demonstrates an influence on blood pressure regulation 
through the renin-angiotensin-aldosterone system.  The afferent and efferent signaling 
from the kidneys are also considered central sympathetic nervous system stimulation as 
the kidneys receive and distribute sympathetic action. (64)  While the baroreceptors alter 
sympathetic and parasympathetic activities, renal afferent signaling only plays a role in 
central sympathetic activity.  By inhibiting this signaling through renal denervation, 
sympathetic afferent action is dampened, reducing overall central sympathetic output.  
Ultimately, this reduction serves to decrease blood pressure, as well as other 
cardiovascular hemodynamics controlled by sympathetic nervous system activity. (65)  
An important pathophysiological condition directly related to the renin-
angiotensin-aldosterone system to note, besides blood pressure dysregulation, is heart 
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failure (HF).  As a disease, HF is a major concern in the healthcare world as it is 
associated with extreme mortality and morbidity; in 2013, the cost was roughly $32 
billion within the United States alone.  Renal denervation (Figure 7) has become an 
important method of HF treatment as patients with HF have an increased stimulation of 
the renal sympathetic system.  This results in fluid volume overload, sodium retention 
and additional renal sympathetic system activation, thereby creating a continual cycle of 
recurring disease. (66) 
      
Figure 7. Physiological impact of hypertension and heart failure. The renin-
angiotensin-aldosterone system is triggered by the kidneys and brain in pathological 
states of hypertension and heart failure.  Renal denervation is illustrated as a non-
pharmacological method of intervention for the treatment of resistant hypertension and 
heart failure. RAAS, renal-angiotensin-aldosterone system; RDN, renal denervation. 
Figure taken from (66). 
 
Another therapeutic method of interest in blood pressure regulation is spinal cord 
stimulation.  Along with vagus nerve stimulation, spinal cord stimulation is considered 
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neuromodulation that has been employed in the clinical setting since the 1980’s.  Initially 
used for epilepsy, depression, refractory angina and chronic pain management, spinal 
cord stimulation has gained interest in the research world for its use in patients with HF. 
(67)  Through clinical investigation, spinal cord stimulation has shown to produce a 
“cardioprotective effect.”  This is substantially achieved through parasympathetic 
stimulation via the vagus nerve, which serves to decrease blood pressure and heart rate.  
Continued preclinical efforts are currently being done to evaluate the cardioprotective 
results of this therapy in the hopes of gaining further insight into the treatment of HF and 
other cardiovascular diseases. (66) 
A final therapeutic method to be considered briefly here is carotid angioplasty and 
stenting (CAS).  CAS is a procedure used to treat carotid stenosis in patients for the 
prevention of ischemic stroke.  Well-known complications for this intervention have been 
identified, including alterations in the baroreflex.  “Hemodynamic depression” can result 
during or after the CAS procedure due to activation of the baroreflex by the stenting 
balloon or carotid stent pressing against the baroreceptors.  This mimicking of elevated 
blood pressure can lead to hypotension, decreased TPR and lowered heart rate.  Studies 
have shown that CAS can decrease the baroreceptor function or increase parasympathetic 
nervous system action in the acute setting. (68) 
Very limited published research has been provided for the chronic effects of CAS 
on the baroreceptors and the consequential alterations in cardiovascular hemodynamics. 
(69)  One case study from 2014 of a patient undergoing CAS reported the patient 
experiencing hemodynamic instability following stenting and for a sustained period 
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thereafter, which required vasopressor support for the following week. (68)  Vasopressors 
are pharmaceutical medications which serve to increase blood pressure in the acute, 
critical setting. (70)  Other studies have attempted to review longer periods of time post-
carotid artery stenting, however, many limitations, including small numbers of studied 
patients, have made this area of study challenging.  It has been proposed that the 
underlying disease, such as carotid atherosclerosis, coronary heart disease and stroke, is 
the contributor to decreased baroreceptor sensitivity, rather than CAS itself.  Therefore, 
further investigation is warranted to determine the effects of CAS on baroreceptor 
function and blood pressure regulation in the chronic setting. (69) 
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SPECIFIC AIMS 
 The immense amount of published research on the aortic and carotid 
baroreceptors and the use of different cardiovascular devices in the clinical setting 
reflects the importance of each subject in its own separate element.  However, it is of 
great speculation that research published reflecting both considerations together is quite 
limited.  This literature review section therefore serves to summarize the current 
understanding of the effects of three different cardiovascular devices on the baroreflex in 
the cardiovascular system.  The three devices to be reviewed include: intra-aortic balloon 
pumps (IABP), left ventricular assist devices (LVAD) and carotid sinus stimulators.  
An investigation into the current evidence about standard treatment with IABPs, 
LVADs and carotid sinus stimulators in cardiology patients may shed light on 
baroreceptor activity involvement and any potential implications.  Conclusions will be 
drawn on the significance of the physiological role baroreceptors play in modulating 
blood pressure during the use of these cardiovascular devices in the clinic.  Given the 
limited amount of published work, it will most likely be determined that further research 
and consideration will need to be established from a cardiovascular standpoint in order to 
better understand the relationship between all components. 
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PUBLISHED STUDIES 
 
Intra-aortic balloon pumps 
The intra-aortic balloon pump is a device used for its counterpulsation mechanism 
and has been considered “the most widely used mechanical circulatory support device 
because of its ease of use, low complication rate, and fast manner of insertion” (71).  
Mechanistically, the device functions within the descending aorta to inflate during 
diastole and deflate during systole, mainly to increase oxygen delivery in the coronary 
arteries and reduce the afterload on the heart, in turn reducing oxygen demand and 
myocardial workload.  IABPs are used for temporary cardiovascular circumstances, such 
as during a percutaneous coronary intervention (PCI), to allow for sufficient myocardial 
oxygen perfusion to make up for a heart that cannot pump efficiently on its own. (72)  
The standard patient case that warrants use of an IABP typically is for cardiogenic shock, 
high-risk PCI and acute myocardial infarction. (71)   
An IABP is made up of generally three main parts: the console, a balloon catheter 
and driving gas that fills the balloon.  The console functions to provide a precise amount 
of gas into the balloon catheter, typically helium, at a set time point, followed by removal 
of the gas thereafter.  It is important to note that patients undergoing procedures with 
IABPs also have constant measurements of heart rate and blood pressure through the use 
of electrocardiograms.  These measurements come from a monitoring system within the 
console, which then processes the information and generates a “trigger signal” to increase 
or stop gas flow into the balloon. (73) 
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Figure 8. IABP placement and balloon use.  Diagram depicting balloon 
placement and mechanism.  During diastole, the balloon inflates and allows for increased 
perfusion of the heart vessels, while during systole, the balloon deflates and lessens the 
afterload on the left ventricle.  Figure taken from (74). 
 
The concept of counterpulsation (Figure 8) was initially established during the 
1950’s in dogs when researchers discovered that impeding systolic blood pressure, 
enhanced diastolic or coronary blood pressure and, thereby significantly increased 
coronary blood flow to the heart.  Further studies built onto this new concept by 
discovering experimental techniques of augmenting aortic diastolic pressure, as well as 
reducing systolic blood pressure through an arterial cannula and coordinated infusion and 
extraction of blood.  It was during this time that experimental techniques of modifying 
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blood pressure changes were found to be dependent on a few factors, which Weber et. al 
have described as “the volume of blood displaced, the pressure-volume relationship of 
the aorta, the position and size of the arterial cannula, and proper synchronization with 
the cardiac cycle.” (75)   
By the 1960’s, the earliest forms of IABPs were created through the 
implementation of latex tubing wrapped around the end of a catheter containing several 
holes in its side, and blocking one end of the catheter in order to expand and depress the 
latex balloon through the side holes.  This mechanistic approach formed a “closed 
system” through which carbon dioxide could be contained for balloon expansion through 
alternating employment of air pressure.  Pairing this approach with measurements from 
an electrocardiogram, the balloon was timed to deflate during systole and inflate during 
diastole.  This novel method was further implemented within the aorta to manipulate 
cardiovascular hemodynamic responses of decreased end diastolic blood pressure and 
increased diastolic blood flow within the arterial circulation. (73) 
The same investigators who performed novel IABP experiments in dogs 
continued their efforts in the clinical setting through studies of small numbers of patients 
who suffered from cardiogenic shock following myocardial infarctions.  Their efforts 
showed promising results as the initial devices provided hemodynamic support for 
patients, reversing the infarction shock state with minimal side effects after device use.  
This discovery in the clinical setting set the stage for others to begin implementing IABPs 
in their research, which eventually lead to further positive results of the device’s use.  
Patients with myocardial infarction-induced shock had enhancements in “myocardial 
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metabolism” while using the device, as well as implementation during critical 
procedures; procedures including “coronary angiography and left ventriculography” 
during IABP use were successfully completed in emergency situations. (75)   
Continued efforts in the research and development of IABPs lead to several 
discoveries of valuable information for the device’s use in a range of clinical settings.  By 
the 1970’s, researchers were implementing the device in HF models, showing beneficial 
effects (Figure 9).  The topic of HF patients and IABP use will be discussed in greater 
detail in upcoming sections of this literature review.  Additional studies found further 
promising results in improved cardiovascular hemodynamics while using 
counterpulsation techniques; the detection of improved patient prognosis provided the 
basis for IABP support immediately following cardiogenic shock. (73) 
 
 
Figure 9. Hemodynamic changes with and without implementation of an IABP. 
Waveform alterations demonstrating the differences in blood pressure between assisted 
and non-assisted device counterpulsation.  Figure taken from (71). 
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In current medical practice, the most typical indication for use of an IABP is for 
patients who have had a myocardial infarction, trailed by cardiogenic shock, the two 
pathologies most studied during the development of modern-day IABP devices.  The 
largest randomized clinical trial studying cardiogenic shock involving IABPs showed that 
most patients presenting with myocardial infarctions ended up having a PCI, as well as 
stent deployment in the affected vessel, or vessels, if multi-vessel disease was present.  
During use, the device’s mechanical support allows for enhanced coronary blood flow 
and peak diastolic blood pressure, which are beneficial to patients in the acute, 
emergency situation involving a heart attack and ensuing infarction shock. (76)  Problems 
observed from IABP use have been noted as “aortic wall damage, femoral artery 
insufficiency, and thrombocytopenia,” though patient cases have shown these 
complications to be uncommon. (75)  The researchers concluded that further 
investigation was warranted to prove a stronger indication for IABPs in the setting of 
cardiogenic shock post-myocardial infarction, as compelling evidence to show a robust 
clinical impact was not seen. (76) 
In addition to myocardial infarction followed by cardiogenic shock, other 
recognized indications for IABP use include myocardial infarction alone, cardiac surgery 
and patients undergoing high-risk PCI’s. On the other hand, patient profiles that contain 
contraindications for use comprise severe peripheral vascular disease, significant aortic 
regurgitation, active bleeding, uncontrolled coagulopathy, sepsis and severe aortic vessel 
pathology.  As previously mentioned, the lack of robust clinical data supporting the use 
of IABPs for these clinical indications contributes to the current ambiguity surrounding 
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the appropriate use of the device; therefore, continued research efforts are needed to 
provide more insight. (74) 
Additional patient profiles of interest are those suffering from HF.  IABPs are 
most commonly used in acute HF to improve myocardial recovery through mechanical 
circulatory support until the patient can be weaned off of the device.  Although most 
published literature discusses IABP use in the setting of acute HF, a recent preliminary 
study has shown promising results for the use of IABPs long term for patients with 
chronic HF. (77)  Chronic heart failure is a disease characterized by a worsening of HF 
symptoms, either acutely, or a slow deterioration of previously diagnosed chronic HF.  
The left ventricle function is usually compromised, though there are HF patients with 
preserved left ventricular function.  Patients with HF tend to present with “acute 
pulmonary edema, hypertensive heart failure, decompensated chronic heart failure, and 
cardiogenic shock.”  Most organ systems are affected as blood flow is reduced, leading to 
decreased tissue and organ perfusion, as well as congestion. (78)   
Given the now widely accepted use of IABPs in the clinical setting, it is of 
interest to discover that very limited published literature has been established for the 
effects of IABP use on the baroreceptors.  As previously considered, IABPs have been 
intensely studied for their effects on the left ventricle and the device’s intended use, but 
effects on the autonomic system regulation in comparison have been almost nonexistent.  
(79)  In 1971, Normann et. al. published a paper investigating arterial “baroreceptor 
output (BRO)” during IABP use in dogs.  Heart rate and aortic arch pressure were 
measured, while electrocardiogram readings were monitored for proper timing methods.  
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Aortic and carotid baroreceptor activities were monitored during each circulatory cycle 
on a beat-by-beat basis.  The investigators found that the BRO readings typically seen 
during systole were lessened, and were also equivalent to or less than BRO readings 
during diastole.  It was also noted that baroreflex responses from both the carotid and 
aortic locations were similar in their hemodynamic modifications.  From these 
experiments, it was clear that IABPs altered baroreceptor responses in the acute setting.  
Immediate changes during systole and diastole can be seen, demonstrating the high 
sensitivity of the baroreceptors while the device is in use.  The experimental data from 
these studies show that IABPs produced a similar effect to that of increasing heart rate 
two-fold, therefore altering autonomic output to the heart and peripheral vasculature. 
Their discussion reiterates the concerns and potential benefits surrounding baroreceptor 
control and ensuing autonomic hemodynamic changes during procedures with 
mechanical circulatory assist devices, such as IABPs. (80) 
Another publication by Feola et. al. reviewed IABPs and the baroreflex in dogs 
during their considerations of hemodynamic changes in induced acute left ventricular HF.  
Measurements of BRO were recorded, and similar results to Normann et. al. were 
observed.  IABP use again increased BRO during diastole and decreased BRO during 
systole, with the overall result being greater during diastole.  Therefore, it again was 
detected that IABP use significantly changed the output signals of the baroreceptor 
response, and that acutely, the association between the device and the body’s autonomic 
response are of vital importance to consider during similar procedures. (81) 
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Fresiello et. al. produced a paper focused on observing the baroreflex while 
IABPs were in use, while noting changes in heart rate, venous tone and TPR, to evaluate 
the potential positive effects the device may have on cardiovascular hemodynamics.  As 
HF and hypertensive patients could benefit from a reduction in heart rate and TPR, 
thereby decreasing the workload of the ventricles, the investigators aimed to create a 
“hybrid model” to test their hypotheses.  This model was “computational and hydraulic,” 
and studied timing effects of IABPs on the baroreflex, as well as how alterations in 
baroreflex activity would change cardiovascular hemodynamics in a simulated patient.  
The hybrid model was a combination of physical and computational submodels based off 
of previous work that mimicked systemic and pulmonary circulation.  Within this system, 
experiments within a mock aorta could be produced to mirror actual baroreceptor 
responses to pressure changes.  As discovered in previously mentioned work, the 
investigators found that IABP use impacted baroreceptor activity; counterpulsation 
during diastole stimulated the baroreflex, with an overall result of an increase in afferent 
signaling.  The outcomes reiterate the knowledge that during device use, the inflation of 
the balloon stimulates the baroreceptors by causing additional pressure during the 
diastolic phase, thereby increasing baroreflex action and the resultant hindering of the 
sympathetic nervous system.  Additionally, they also noted that the timing and duration 
of the balloon inflation was vital to altering TPR, heart rate and venous tone, as the 
counterpulsation created opposing effects of the sympathetic system depending on when 
inflation occurred. (79) 
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Left ventricular assist devices 
Mechanical circulatory assist devices have evolved tremendously since their 
initial development during the 1950’s.  The class of devices known as left ventricular 
assist devices, or LVADs, have gained immense clinical use as device development has 
progressed over time. (82)  The main elements of LVADs are a cable, known as a 
driveline, that is inserted into the patient’s chest, pump and inflow and outflow cannulas, 
which serve to supplement the role of the patient’s own heart.  The pump is placed at the 
apex of the left ventricle and is connected to the inflow and outflow tubes.  Blood from 
the inflow side of the left ventricle is sent through the pump, followed by passage into the 
outflow side and through the aorta.  Various types of LVADs allow for differing blood 
flows, as well as pulsatile or continuous pumping.  The driveline serves to link the heart 
pump to a driver outside of the patient’s body that houses a system controller.  A battery-
operated unit is connected to the system that serves as a power source, regulator of 
system speed and power, establishes data collection, provides alarms and completes 
diagnostic monitoring of the device. (84)  Figure 10 below illustrates the overall device 
placement for patient use. 
A major clinical indication for LVAD use is HF.  As previously discussed, HF 
poses a high risk for morbidity and mortality while contributing to immense financial 
burdens within the healthcare world.  Regardless of continued efforts in 
resynchronization devices and pharmacotherapy, several patients suffering from the 
disease reach end-stage HF.  Options for patients during end-stage HF are limited; LVAD 
use or a heart transplant are typically the only therapeutic approaches remaining.  Given 
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that heart transplant procedures are restricted due to the number of available donor 
organs, LVAD use has been established as a “bridge to transplant or as a destination 
therapy” for those who do not meet the criteria for a heart transplant. (83)  
With the development of the first mechanical circulatory assist devices in the 
1950’s, many efforts were made thereafter to produce device pumps for short-term 
support during surgeries and interventions.  Patients undergoing cardiopulmonary bypass 
surgery were placed on pump therapy if their cardiac output was decreased post-
procedure.  In a little more than ten years since the first mechanical circulatory device 
was implemented in the clinical setting, the “Artificial Heart Program” was developed for 
the research and development of devices, which could provide not only acute, emergency 
circulatory support, but also long-term support for patients with failing hearts.  By 1969, 
the first implantable LVAD was successfully implemented.  As physicians began 
regressing from the use of total artificial hearts due to their increased risk of 
complications, LVAD therapy was moving forward with development of long-term use.  
Many generations of the device have been modified over time through current medical 
practice; LVAD therapy can be used for patients awaiting donor hearts who need bridge 
to treatment support, or others who are ineligible for heart transplants and receive long-
term support, also known as “destination therapy.” (83) 
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Figure 10 Left ventricular assist device.  Components of a current standard LVAD for 
patients with an indication for device use. The pump is located near the left ventricle and 
contains a tube which sends blood through the aorta. The driveline is seen inside and 
outside of the body via the skin line, where it connects the pump to the system controller 
and external battery pack. Figure taken from (85). 
  
 The current indications for LVAD therapy are provided as guidelines for device 
use, however, the final decision to implant the device in a patient is the product of several 
consults with different specialists and collaborative efforts of many teams.  Suitable 
patients must have previously exhausted all optimal medical therapy options, as well as 
have at least one of the following clinical indications: three or more hospitalizations 
within the last year, a left ventricular ejection fraction of less than 25%, ionotropic 
support dependence, early right ventricular dysfunction, or advanced kidney and/or liver 
failure “secondary to hypoperfusion” and to elevated “left ventricular filling pressures.”  
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It is important to note that patients who are considering LVAD therapy are typically also 
presented with the option of total heart transplant, given that their end-stage HF meets the 
criteria for either therapeutic technique. (86) 
 Similar to IABPs previously reviewed, LVADs and the baroreflex have been 
frequently researched; however, their considerations together are sparse in the scientific 
literature.  The LVAD has established its critical use for patients needing mechanical 
circulatory support, especially those with HF.  Jansen-Park et. al. have discussed the 
importance of considering the effects of LVADs and the baroreflex to gain further 
knowledge of the physiological changes taking place during device use.  The 
investigators implemented a hydraulic model, named “mock heart circulation loops,” that 
mimic the cardiovascular system and have reproducible effects similar to the human 
body.  While using this model, investigators found it challenging to establish autonomic 
regulatory function of cardiac output and MAP.  The background information supporting 
their investigation described the baroreceptor response as altering the afterload of the 
hydraulic model, as well as TPR, venous tone and heart rate; their new model took all 
autonomic regulation into consideration and adjusted accordingly in order to study 
LVADs without confounding issues.  The results indicated that changes in LVAD speed, 
which served to alter the preload on the heart, altered cardiovascular hemodynamics.  As 
the device increased in speed, the pressure within the aorta increased, whereas the 
pressure in the left ventricle decreased, and were the result of baroreflex alterations.  The 
investigators discussed that studying further baroreflex fluctuations could shed additional 
light on pathophysiological states.  The mock heart circulation loop model proved to be a 
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vital tool for observing LVAD effects and the baroreflex, which investigators concluded 
provides potential benefit for future research on mechanical circulatory assist devices, 
their clinical application and resulting physiological outcomes. (87) 
 Another publication by Tank et. al. studied nine HF patients with implanted 
LVADs and the device’s direct effect on the baroreflex.  The investigators hypothesized 
that LVADs with a continuous flow, as opposed to pulsatile flow, would alter the 
baroreflex ability to control sympathetic output to the heart, and ultimately intensify 
sympathetic activity.  The newly established continuous flow systems have proven 
superior to pulsatile flow devices in “cardiovascular morbidity, reoperations for device 
repair or replacement, and total mortality,” providing a promising option for patients 
suffering from end-stage HF.  However, the investigators argued that as these more 
modern devices have been implemented, their resulting effects on cardiovascular 
hemodynamics may be problematic as continuous flow is linked with significant 
baroreflex regulation issues.  Hemodynamic variables measured in the nine patients 
studied included: brachial and finger blood pressure, respiration, muscle sympathetic 
nerve activity and heart conductance via electrocardiograms.  The patients went through a 
series of autonomic function testing, as well as changing seven of the patient’s devices to 
have an increased speed.  Baroreceptor function was evaluated and the investigators 
concluded that low pressure pulses from LVAD use is adequate enough to generate 
sympathetic activity via baroreflex activation.  One of the experiment’s significant 
findings showed that the regulation of baroreflex muscle nerve sympathetic activity was 
unexpectedly conserved, resulting in decreased sympathetic output.  Additionally, given 
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the compromised contractility status of each patient’s heart, it was surprising to discover 
that sympathetic activity was low.  The results from this study contest the concept that 
pulsatile flow and normal pressures are necessary in order to preserve cardiovascular 
hemodynamic stability.  The investigators concluded that continuous flow LVAD use in 
patients with HF is satisfactory to conserve cardiovascular functioning through 
baroreceptor regulation. (88) 
 A paper published in 2014, not long after the work produced by Tank et. al., 
stated that Tank’s group was the only paper published examining continuous flow LVAD 
use and effects on the baroreflex within the clinic setting.  Fresiello et. al. therefore 
wanted to implement different study models in vivo in order to determine which model 
may be realistic for the study of the device and autonomic functioning.  The baroreflex 
involvement in varying cardiovascular hemodynamic states creates a challenging 
situation when analyzing data from animal models, which the investigators state is due to 
the intricacy of several physiological interactions.  The investigators used a hybrid device 
model that analyzed data generated during LVAD use within animal models in normal, 
pathological and device-assisted states.  Their findings revealed that the hybrid device 
was able to mimic physiological and pathological hemodynamic states within the animal 
model, as well as the effects of LVAD use on baroreceptor regulation and unloading of 
the left ventricle at altering pump speeds.  One component of the study looked at afferent 
and efferent sympathetic nerve action during LVAD use, and found similar results to the 
work produced by Tank et. al. in patients with end stage HF; as device speed increased, 
sympathetic action declined, indicating the baroreceptor control of autonomic activity.  
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Fresiello et. al. concluded that the model used in their experiments was able to adjust 
without difficulty to generate varying hemodynamic states and study the effects of LVAD 
use, and should be considered for future work in human studies.  The paper discusses the 
importance of further studying mechanical circulatory assist devices, such as the LVAD, 
given their increasing usage and development, in order to understand the devices in 
varying physiological states and modify their use to maximize potential benefit in the 
experimental and clinical setting. (89) 
 A final reviewed paper by Markham et. al. compared physiological responses in 
patients with and without pulsatile LVADs.  As previously mentioned, the early 
generation of pulsatile flow devices were succeeded by continuous flow, or nonpulsatile, 
devices as device development matured.  The investigators in this study wanted to 
examine the long-term effects of continuous flow LVADs in patients who would not be 
receiving a constant pulse from their devices.  The paper describes the challenges 
surrounding blood pressure measurements without a consistent device pulse, which can 
contribute to “an increased risk of uncontrolled hypertension and possibly stroke,” as 
well as other potential complications.  They speculated this could be due to the constant, 
and at times increased, sympathetic output due to the lack of device pulsation.  Without a 
consistent pulsatile mechanism, the baroreflex is not triggered as effectively, reducing the 
afferent nerve signaling and causing an increased sympathetic response.  The increased 
sympathetic activity is the result of a decreased inhibition via the baroreceptor response, 
as the lack of continual pulsation did not stimulate the reflex as effectively.  The study’s 
hypothesis was that patients with continuous flow LVADs would have increased 
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sympathetic activity compared to those with pulsatile devices.  Measurements were taken 
while patients were at rest and while upright.  Results showed that for both resting and 
upright patients, those with continuous flow devices did indeed have elevated 
sympathetic nerve activity compared to patients with pulsatile devices and healthy 
control individuals.  The investigators discussed different prospective mechanisms for 
their results; the most plausible idea was less baroreceptor activation, but they also 
discussed other potential mechanisms.  For example, constant baroreceptor activation, as 
in the case of pulsatile flow devices, quickly causes baroreceptor desensitization, which 
does not occur in continuous flow devices.   The paper describes that theoretically, 
endothelial cell function could play a role in increased sympathetic discharge as a 
decrease in pulsation reduces shear stress, and less nitric oxide is generated.  A decrease 
in nitric oxide weakens the vasodilatory effects of endothelial cells, as well as produces 
an escalation in sympathetic activity.  Another potential mechanism the researchers 
postulated was humoral factors, such as products of the renin-angiotensin-aldosterone 
system, may add to the observed increased sympathetic activity in patients with 
continuous flow LVADs.  As described in other papers reviewed in this section, 
Markham et. al. also expressed the need for further investigation in order to gain more 
advanced knowledge on the clinical impact of continuous flow LVADs and their effects 
on cardiovascular hemodynamics in patients implanted with these devices for chronic 
use. (90) 
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Carotid sinus stimulators 
 As the baroreflex and its association with blood pressure regulation became better 
understood, interest arose amongst the scientific community to further explore potential 
beneficial methods of therapeutic intervention.  As early as the 1850’s, in vivo studies 
were conducted on the carotid sinus and the discovery of the baroreflex in modulating 
blood pressure was established.  In the 1960’s, the development of an implantable device 
with two carotid sinus electrodes was created to study blood pressure changes in dogs 
with hypertension.  A short time thereafter, the first clinical implementation of this same 
procedure in two patients with hypertension was performed. (91)  Hypertension was the 
first disease of interest given its direct relation to blood pressure dysregulation.  Early 
clinical stages of research and development were slow in nature due to the limitations of 
the then present technology, as well as the introduction of favorable pharmaceutical 
agents. (92)  Additionally, initial clinical data supporting baroreflex mechanisms in 
hypertensive patients was only understood in an acute sense; baroreceptor activation was 
viewed as a short-term mechanism with transient properties. (91) 
 Currently, the most studied carotid sinus stimulator undergoing clinical 
investigation is made up of three parts: leads for use within the carotid sinus, a 
programmer that is used externally and an implantable pulse generator.  Both carotid 
sinuses may be targeted for stimulation, or a single side is intervened on through newer 
device systems.  The ends of the leads contain electrodes, or a single electrode in newer 
device systems, which deliver stimulation to the baroreceptors either in bursts or 
continuously.  The stimulation can be adjusted for different “voltage protocols” that 
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allow for modifiable impulse amplitudes and intervals.  The leads are attached to the 
implantable pulse generator that is surgically inserted into an infraclavicular pocket 
within the patient.  The external programmer is not connected to the patient and serves to 
test the patient’s device routinely for cardiovascular hemodynamic changes. (92)  Figure 
11 below demonstrates the internal location of the carotid sinus leads and location of the 
pulse generator. 
 
Figure 11 Carotid sinus stimulator.  Depiction of a carotid sinus stimulator set of leads 
affixed within the carotid sinus and a pulse generator that is implanted within the 
patient’s infraclavicular pocket.  Figure taken from (92). 
 
Due to the fact that carotid sinus stimulators are still in clinical trial 
investigational phases, there are no current Food and Drug Administration indications for 
use.  Patients who enroll into clinical trials involved with carotid sinus stimulators 
typically have either treatment resistant hypertension or chronic HF.  Patients who 
present with treatment resistant hypertension are generally categorized as those with 
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“blood pressure that remains above goal in spite of the concurrent use of three 
antihypertensive agents of different classes.” (93)  These patients present with elevated 
sympathetic nervous system activity, as well as decreased parasympathetic activity of 
heart rate control.  Carotid sinus stimulators promote baroreflex activation in order to 
reverse these autonomic functions by increasing parasympathetic activity and decreasing 
sympathetic activity, ultimately serving to establish an equilibrium between the two 
opposing outputs and depressing blood pressure. (94)  It is also important to note that as 
sympathetic tone is lessened through this therapeutic approach, the renin-angiotensin-
aldosterone system output is decreased, thereby increasing excretion by the kidneys. (95)  
Although this newer therapeutic approach has shown promising data and hope for 
patients suffering from treatment resistant hypertension, the response is not consistent, 
and some individuals undergoing carotid sinus stimulation do not generate a response 
whatsoever. (94) 
Chronic HF has been a more recent disease of interest by investigators studying 
carotid sinus stimulators, with a patient population focused on those with reduced left 
ventricular ejection fractions.  Similar to treatment resistant hypertension, patients 
suffering from chronic HF have increased sympathetic and decreased parasympathetic 
activity imbalances that advances the development of HF over time.  Current therapies 
concentrate on balancing neurohormonal factors via pharmacotherapy; typically, renin-
angiotensin-aldosterone inhibitors and beta-blockers are prescribed.  With a lowered left 
ventricular ejection fraction, the chronic HF patient’s heart is unable to provide adequate 
systemic and organ perfusion on a continuous basis.  These conditions place the body 
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into a state such that sympathetic activation and parasympathetic inhibition are constantly 
attempting to supply the necessary neurohormonal means of restoring physiological 
homeostasis.  Due to this, the stress on the heart causes further decrease in cardiac output 
and function, and a perpetual cycle continues.  As with treatment resistant hypertension, 
carotid sinus stimulation (Figure 12) looks to activate the baroreflex in an attempt to 
reverse the autonomic disparity in chronic HF patients. (96) 
 
 
Figure 12 Carotid sinus stimulation intervention in patients with chronic heart 
failure.  Baroreflex activation therapy is modeled with the intent of breaking the 
continual cycle of sympathetic nervous system activation in patients with chronic HF.  
Pharmacotherapy interventional options are also noted.  Figure taken from (96). 
 
Unlike the previous cardiovascular devices discussed in this literature review, it is 
much more clear the effects that carotid sinus stimulators have on the baroreflex.  For 
consistency, a few published articles will be reviewed briefly here.  A publication by 
Gronda et. al. looked at the effects of baroreflex chronic activation in eleven patients with 
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chronic HF at a single investigational center.  Data measured included muscle 
sympathetic nerve activity, blood pressure and heart rate, as well as electrocardiogram 
measurements.  Also, quality of life, HF classifications, walk tests, lab data, left 
ventricular ejection fraction and safety data were assessed.  Two weeks after patients 
were implanted with the carotid sinus stimulator, the device was turned on, and 
baroreceptor stimulation therapy was increased, as tolerated, to a stimulation protocol 
desired pulse level.  The investigators followed the study participants for six months; 
their results concluded that chronic carotid sinus stimulation of the carotid baroreceptors 
decreased sympathetic activity in these patients.  Additionally, they noted that there was 
marked improvement in baroreflex response, which is normally compromised in chronic 
HF patients, in turn generating an overall positive effect on cardiovascular health. (97) 
Another publication by Wallbach et. al. aimed to study the effects of carotid sinus 
stimulation on ambulatory blood pressure for patients with treatment resistant 
hypertension.  Ambulatory blood pressure measurements provide insight to regular blood 
pressure levels that may be hindered by “white coat hypertension” that is prevalently seen 
in some patients while blood pressure measurements are taken in a clinic setting. (98)  
The investigators pointed out that inadequate data are currently present for day-to-day 
blood pressure alterations for patients implanted with baroreflex activation devices, in 
comparison to blood pressure readings produced in the clinic.  Measurements of 
ambulatory blood pressure were taken pre-procedure and six months after device 
activation.  The investigator’s results showed that ambulatory blood pressure readings 
were significantly lowered, along with a decrease in prescribed antihypertensive 
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medications.  As a novel investigation on ambulatory blood pressure and carotid sinus 
stimulators, the investigators concluded that for patients living with treatment-resistant 
hypertension, baroreflex activation therapy could be a potential innovative approach to 
decrease overall cardiovascular risk factors. (99) 
A third publication by Georgakopoulos et. al. presented a literature review 
focused on carotid sinus stimulation in patients with chronic HF who maintained 
preserved left ventricular ejection fractions.  HF with preserved ejection fraction 
(HFpEF) is considered to be as serious of a public health concern as HF with diminished 
left ventricular ejection fraction.  The investigators point out that as of the paper’s 
publication in 2011, there have not been any randomized clinical trials showing 
significant benefit for HFpEF patients in any therapeutic approaches. (100)  A further 
investigation into the literature provided very little additional information.  An abstract 
from a more recent publication in 2014 again confirmed that there has not been a 
successful treatment option discovered for HFpEF patients, with researched potential 
therapeutic approaches including pharmacotherapy, carotid sinus stimulation, heart 
pacing and lifestyle modification through diet and exercise.  At this time, it appears that 
the goal is to manage HF symptoms while research and development continues to search 
for a more promising therapy. (101)  Georgakopoulos et. al. describe in their review that 
hypertension is the chief comorbidity in HFpEF patients, therefore current efforts in 
studying carotid sinus stimulation and hypertension may provide promising insight for 
future therapeutic options.  Also, the review summarizes other potential advantages of 
baroreflex activation besides hypertension management, including “regression of left 
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ventricular hypertrophy,” equilibrium establishment between autonomic imbalances, 
disruption of the renin-angiotensin-aldosterone system, vessel dilation and kidney 
function conservation.  The review reiterates that although there are no currently 
available treatments, great efforts are being put forth to research carotid sinus stimulation 
in the hopes of developing the first effective therapy for patients living with HFpEF. 
(100) 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Blood pressure regulation is managed on an instantaneous basis in order to 
maintain cardiovascular homeostasis.  As mechanosensitive receptors activated by 
distension, the baroreceptors play a crucial role in modulating MAP through autonomic 
system balances.  Located within the aortic arch and carotid sinuses, baroreceptor 
activation provides signaling for sympathetic activation and parasympathetic inhibition, 
whereas baroreceptor disengagement produces the opposite, with inhibition of 
sympathetic nerve signaling via increased parasympathetic activity.  These actions result 
in physiological changes in MAP, heart rate, heart contractility and TPR.   
 Alterations from a steady state in blood pressure management are swiftly adjusted 
in order to reduce any unwanted stressors on the cardiovascular system.  Over time, 
however, continued stress eventually leads to dysregulation.  In the case of MAP, 
hypertension is the main pathophysiological state that results from continued, elevated 
blood pressure levels.  As the leading risk factor for disease, hypertension therapy and 
management efforts have been robust as a remarkable proportion of the population are 
effected and as healthcare costs continue to skyrocket.  Lifestyle modifications through 
diet and exercise are executed as initial and continued efforts to attempt to reduce 
elevated blood pressure levels.  Additional therapeutic approaches are provided, as 
needed, to patients living with hypertension.  An abundance of pharmaceutical agents has 
been established for use in the clinic that target different components of blood pressure 
regulation.  Several antihypertensive agents can be provided as potential therapies, with 
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options to alter dosage, switch to a different class of drugs, or to use as a combination 
therapy with multiple antihypertensive agents.   
In cases where lifestyle modification and pharmacotherapy options have been 
exhausted, patients may seek help through interventional and device therapies.  As the 
baroreflex provides the integral role in blood pressure regulation, different interventions 
and devices have been shown to have varying effects on the aortic and carotid 
baroreceptors and their ensuing actions.  As previously considered, much published 
literature has been produced on the baroreflex and its role in cardiovascular 
hemodynamic stability, as well as a vast abundance of knowledge surrounding device 
therapies.  It is the combination of these efforts that is lacking in established data and 
knowledge that makes the considerations for this literature review so intriguing. 
With the development of IABPs, patients needing temporary mechanical support 
have found profound success.  Strong efforts have been made to develop next generation 
models based on prior safety and efficacy data in order to provide topline healthcare 
options for those with significant cardiovascular disease.  Given that the device is 
inserted into a location in close proximity to the aortic baroreceptors, IABPs can be 
anticipated to prompt changes in autonomic nerve output and therefore may alter 
cardiovascular function.  Changes in IABP counterpulsation also may play a role in 
varying physiological responses, which could serve as a potential therapeutic 
modification in future studies.  Additionally, further investigation into short versus long 
term IABP use may shed additional light on physiological changes produced by device 
effects, and how to transform these responses into positive therapeutic benefit for 
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patients.  As very limited published information is known about IABP influence on the 
baroreflex, additional pre-clinical and clinical work needs to be performed in order to 
better understand short and long term effects of device use. 
Heart failure is a disease which plagues a significant portion of the patient 
population and causes many clinical complications, healthcare cost burdens and a 
decreased quality of life for those suffering from the disease.  For several, heart 
transplantation is a typical therapeutic option for those with HF, however, there are some 
individuals who are not suitable candidates for a heart transplant, and therefore need to 
seek other options.  Like IABPs, LVADs are mechanical circulatory assist devices that 
assist HF patients either awaiting heart transplants, or those who are not indicated to have 
the procedure and require chronic support.  Given that HF patients have extremely 
increased sympathetic activity and impaired baroreflex function, further investigation into 
LVAD use is warranted.  Pulsatile and continuous flow LVADs allow for prospective 
insight into the realm of baroreflex control of cardiovascular hemodynamics and 
physiological changes that may be inducible through different flow patterns.  A 
continuous flow and constant baroreflex activation may produce an overall decrease in 
blood pressure and potentially the negative effects produced by hypertension, but 
additional research is required to evaluate long term physiological effects.  New data 
could offer better comprehension on the controlling of LVADs and how this may induce 
positive results in HF patients.  Newer hybrid models mimicking the human 
cardiovascular system can be utilized to test LVADs, as well as other mechanical 
circulatory assists devices, with the potential to delve into more complex clinical 
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situations without direct patient involvement.  As with IABPs, clearly additional research 
and development is warranted to better characterize LVAD pump speed, understand and 
modify blood pressure via baroreflex activation and ultimately alter the path of 
cardiovascular disease through novel therapeutic treatment. 
As the baroreflex became more established through a vast amount of contributors 
to blood pressure regulation research, its impact on cardiovascular physiology in healthy 
and diseased states warranted greater investigational efforts.  The baroreceptors became a 
critical target for potential new treatments for blood pressure dysregulation, as 
hypertension was already known to be a significant risk factor for many comorbidities.  
Through the development of initial carotid sinus stimulators, a hypothetical novel 
therapeutic device for the management of hypertension was established.  Clinical trials 
with early stage device models also showed promising data for patients with chronic HF.  
The device has allowed researchers to manipulate the baroreflex via pulsatile and 
nonpulsatile settings, along with amplitude and interval voltage protocols that provided 
more precise control of baroreceptor activation.  Additional research and development is 
warranted in order to determine the fine-tuning of these settings for device safety and 
efficacy, and in theory, on certain patient populations and on an individual case-by-case 
basis in the future.  With promising pivotal data and current robust efforts in clinical 
research trials, carotid sinus stimulators may one day become the next therapeutic option 
for patients living with treatment resistant hypertension or chronic HF.  As with IABPs 
and LVADs, however, there still remains numerous questions regarding device use, 
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patient selection factors and augmentation of ideal device voltage protocols that are to be 
answered in order to find successful implementation in the clinical setting. 
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